Trial reportAntimicrobial agents and chemotherapy2010
Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.
Trial report in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.
- Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).The Cochrane database of systematic reviews · 2018Pooled it
- High-dose rifampicin and clarithromycin for 4 weeks versus standard-dose rifampicin and clarithromycin for 8 weeks to treat Buruli ulcer: An open-label, individually randomized, controlled trial in Ghana.PLoS neglected tropical diseases · 2026Trial
- Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.Lancet (London, England) · 2020Trial
- Paradoxical reactions in Buruli ulcer after initiation of antibiotic therapy: Relationship to bacterial load.PLoS neglected tropical diseases · 2019Trial
- Long term streptomycin toxicity in the treatment of Buruli Ulcer: follow-up of participants in the BURULICO drug trial.PLoS neglected tropical diseases · 2014Trial
- Antimicrobial resistant bacteria isolated from Buruli ulcer lesions in Ghana.PLoS neglected tropical diseases · 2025Article
- Improved protocols for isolation of Mycobacterium ulcerans from clinical samples.BMC microbiology · 2025Article
- Pharmacokinetics of extended-release clarithromycin in patients with Mycobacterium ulcerans infection.Scientific reports · 2024Article
- Clinical and microbiological predictors of healing in Buruli ulcer disease.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Article
- Memory B-cells are enriched in the blood of patients with acute Buruli ulcer disease: a prospective observational study.BMC infectious diseases · 2023Observational
- Natural antioxidants attenuate mycolactone toxicity to RAW 264.7 macrophages.Experimental biology and medicine (Maywood, N.J.) · 2021Article
- Ultra-short-course and intermittent TB47-containing oral regimens produce stable cure against Buruli ulcer in a murine model and prevent the emergence of resistance forActa pharmaceutica Sinica. B · 2021Article
- Risk Factors Associated with Antibiotic Treatment Failure of Buruli Ulcer.Antimicrobial agents and chemotherapy · 2020Observational
- Pharmacologic management ofExpert review of clinical pharmacology · 2020Review
- Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model.Infection and immunity · 2020Article
- Article
- Buruli ulcer treatment: Rate of surgical intervention differs highly between treatment centers in West Africa.PLoS neglected tropical diseases · 2019Article
- Providing insight into the incubation period of Mycobacterium ulcerans disease: two case reports.Journal of medical case reports · 2019Article
- Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review.Infection and drug resistance · 2019Article
- Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening.PLoS neglected tropical diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have evaluated the clinical efficacy of the combination of oral rifampin at 10 mg/kg of body weight and intramuscular streptomycin at 15 mg/kg for 8 weeks (RS8), as recommended by the WHO, in 160 PCR-confirmed cases of Mycobacterium ulcerans disease. In 152 patients (95%) with all forms of disease from early nodules to large ulcers, with or without edema, the lesions healed without recourse to surgery. Eight patients whose ulcers were healing poorly had skin grafting after completion of antibiotics. There were no recurrences among 158 patients reviewed at the 1-year follow-up. The times to complete healing ranged from 2 to 48 weeks, according to the type and size of the lesion, but the average rate of healing (rate of reduction in ulcer diameter) varied widely. Thirteen subjects had positive cultures for M. ulcerans during or after treatment, but all the lesions healed without further antibiotic treatment. Adverse events were rare. These results confirm the efficacy of RS8 delivered in a community setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.